GlobalData on MSN4d
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
FierceBiotech4d
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson's candidate for $27M
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...
Ventyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical Trials
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...
ENDPOINTS NEWS4d
Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
Investing4d
Sanofi invests $27 million in Ventyx Biosciences
SAN DIEGO - Ventyx Biosciences Inc. (NASDAQ:VTYX), a biopharmaceutical company specializing in oral inflammatory disease therapies, today confirmed a $27 million investment from pharmaceutical giant ...
Business Insider4d
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Ventyx’s relationship with Sanofi may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties ...